by Pharvaris | Feb 7, 2020 | News
Company strengthens executive team with addition of skilled HAE drug developer Leiden, The Netherlands, Feb. 7, 2020 – Pharvaris B.V., a clinical-stage company focused on the discovery and development of novel oral B2-receptor antagonists for the treatment of...
by Pharvaris | Sep 10, 2019 | News
Pharvaris has initiated its first-in-human clinical trial of PHA121 Series B participants led by Foresite Capital with additional new investors Bain Capital Life Sciences, venBio Partners, and Venrock Partners Leiden, The Netherlands, Sept. 10, 2019 – Pharvaris B.V.,...
